Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for bone density in boys with Duchenne muscular dystrophy
ACTRN12610000507088Phase 3Completed
- Sponsor
- The Royal Children's Hospital
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of zoledronic acid in osteopenia and Duchenne muscular dystrophy (DMD) (2 arms), sponsored by The Royal Children's Hospital. Primary endpoint: Change in lumbar spine areal bone mineral density Z-score with volumetric correction at 24 months. Started May 2012; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteopeniaDuchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on ACTRN12610000507088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000507088.